These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 15078145)
1. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Wagman AS; Johnson KW; Bussiere DE Curr Pharm Des; 2004; 10(10):1105-37. PubMed ID: 15078145 [TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase 3: more than a namesake. Rayasam GV; Tulasi VK; Sodhi R; Davis JA; Ray A Br J Pharmacol; 2009 Mar; 156(6):885-98. PubMed ID: 19366350 [TBL] [Abstract][Full Text] [Related]
3. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. Wagner FF; Bishop JA; Gale JP; Shi X; Walk M; Ketterman J; Patnaik D; Barker D; Walpita D; Campbell AJ; Nguyen S; Lewis M; Ross L; Weïwer M; An WF; Germain AR; Nag PP; Metkar S; Kaya T; Dandapani S; Olson DE; Barbe AL; Lazzaro F; Sacher JR; Cheah JH; Fei D; Perez J; Munoz B; Palmer M; Stegmaier K; Schreiber SL; Scolnick E; Zhang YL; Haggarty SJ; Holson EB; Pan JQ ACS Chem Biol; 2016 Jul; 11(7):1952-63. PubMed ID: 27128528 [TBL] [Abstract][Full Text] [Related]
4. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle. Dokken BB; Sloniger JA; Henriksen EJ Am J Physiol Endocrinol Metab; 2005 Jun; 288(6):E1188-94. PubMed ID: 15671078 [TBL] [Abstract][Full Text] [Related]
5. The glamour and gloom of glycogen synthase kinase-3. Jope RS; Johnson GV Trends Biochem Sci; 2004 Feb; 29(2):95-102. PubMed ID: 15102436 [TBL] [Abstract][Full Text] [Related]
6. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Gao C; Hölscher C; Liu Y; Li L Rev Neurosci; 2011 Dec; 23(1):1-11. PubMed ID: 22718609 [TBL] [Abstract][Full Text] [Related]
7. GSK3 takes centre stage more than 20 years after its discovery. Frame S; Cohen P Biochem J; 2001 Oct; 359(Pt 1):1-16. PubMed ID: 11563964 [TBL] [Abstract][Full Text] [Related]
8. GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future. Maqbool M; Hoda N Curr Pharm Des; 2017 Nov; 23(29):4332-4350. PubMed ID: 28714403 [TBL] [Abstract][Full Text] [Related]
9. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance. Højlund K Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125 [TBL] [Abstract][Full Text] [Related]
10. Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors. Wadhwa P; Jain P; Jadhav HR Curr Top Med Chem; 2020; 20(17):1522-1534. PubMed ID: 32416693 [TBL] [Abstract][Full Text] [Related]
11. GSK3: A potential target and pending issues for treatment of Alzheimer's disease. Zhao J; Wei M; Guo M; Wang M; Niu H; Xu T; Zhou Y CNS Neurosci Ther; 2024 Jul; 30(7):e14818. PubMed ID: 38946682 [TBL] [Abstract][Full Text] [Related]
12. Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. MacAulay K; Hajduch E; Blair AS; Coghlan MP; Smith SA; Hundal HS Eur J Biochem; 2003 Sep; 270(18):3829-38. PubMed ID: 12950267 [TBL] [Abstract][Full Text] [Related]
13. Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment. Eldar-Finkelman H; Ilouz R Expert Opin Investig Drugs; 2003 Sep; 12(9):1511-9. PubMed ID: 12943495 [TBL] [Abstract][Full Text] [Related]
14. Recent advances in the discovery of 11beta-HSD1 inhibitors. Boyle CD Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567 [TBL] [Abstract][Full Text] [Related]
15. Characterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling. Zhong H; Zou H; Semenov MV; Moshinsky D; He X; Huang H; Li S; Quan J; Yang Z; Lin S Mol Biosyst; 2009 Nov; 5(11):1356-60. PubMed ID: 19823752 [TBL] [Abstract][Full Text] [Related]
17. A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies. Thapa R; Gupta G; Bhat AA; Almalki WH; Alzarea SI; Kazmi I; Saleem S; Khan R; Altwaijry N; Dureja H; Singh SK; Dua K Int J Biol Macromol; 2023 Dec; 253(Pt 7):127375. PubMed ID: 37839597 [TBL] [Abstract][Full Text] [Related]
18. Anti-diabetic efficacy of KICG1338, a novel glycogen synthase kinase-3β inhibitor, and its molecular characterization in animal models of type 2 diabetes and insulin resistance. Kim KM; Lee KS; Lee GY; Jin H; Durrance ES; Park HS; Choi SH; Park KS; Kim YB; Jang HC; Lim S Mol Cell Endocrinol; 2015 Jul; 409():1-10. PubMed ID: 25802191 [TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention. Van Wauwe J; Haefner B Drug News Perspect; 2003 Nov; 16(9):557-65. PubMed ID: 14702136 [TBL] [Abstract][Full Text] [Related]